CO-ADMINISTRATION OF NORVIR WITH CERTAIN NONSEDATING ANTIHISTAMINES, SEDATIVE HYPNOTICS, ANTIARRHYTHMICS, OR ERGOT ALKALOID PREPARATIONS MAY RESULT IN POTENTIALLY SERIOUS AND/OR LIFE-THREATENING ADVERSE EVENTS DUE TO POSSIBLE EFFECTS OF NORVIR ON THE HEPATIC METABOLISM OF CERTAIN DRUGS. SEE CONTRAINDICATIONS AND PRECAUTIONS SECTIONS.
NORVIR (ritonavir) is an inhibitor of HIV protease with activity against the Human Immunodeficiency Virus (HIV).
NORVIR is indicated in combination with other antiretroviral agents for the treatment of HIV-infection.
Media Articles Related to Norvir (Ritonavir)
First all-oral triple combination therapy for hepatitis C licenced in UK
Source: Liver Disease / Hepatitis News From Medical News Today [2015.01.20]
AbbVie's all-oral, short course (12 weeks for the majority of patients), interferon-free treatments VIEKIRAX (ombitasvir/paritaprevir/ritonavir) and EXVIERA (dasabuvir) are now licensed for use in...
FDA approves Viekira Pak to treat hepatitis C
Source: Liver Disease / Hepatitis News From Medical News Today [2014.12.31]
The U.S. Food and Drug Administration has approved Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) to treat patients with chronic hepatitis C virus...
Published Studies Related to Norvir (Ritonavir)
Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. [2011.09]
OBJECTIVES: Treatment of HIV/tuberculosis (TB) co-infected patients is complex due to drug-drug interactions for these chronic diseases. This study evaluates an intermittent dosing regimen for rifabutin when it is co-administered with ritonavir-boosted atazanavir... CONCLUSIONS: The benefits to HIV/TB co-infected patients receiving rifabutin 150 mg three times weekly or every other day may outweigh the risks of neutropenia observed here in non-HIV-infected subjects, provided that patients on combination therapy will be closely monitored for safety and tolerability.
96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline. [2011.08]
BACKGROUND: In virologically suppressed patients, switching to darunavir/ritonavir monotherapy could avoid resistance and adverse events from continuing nucleoside analogues. METHODS: Two hundred and fifty-six patients with HIV RNA <50 copies/mL on current antiretrovirals were switched to darunavir/ritonavir 800/100 mg once daily, either as monotherapy (n = 127) or with two nucleoside analogues (n = 129)...
Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. [2011.07.15]
BACKGROUND: We compare the effect of 4 different antiretroviral regimens on limb and visceral fat... CONCLUSIONS: ABC-3TC- and TDF-FTC-based regimens increased limb and visceral fat at week 96, with a similar prevalence of lipoatrophy. Compared to the EFV group, subjects assigned to ATV-r had a trend towards higher mean percentage increase in VAT. CLINICAL TRIALS REGISTRATION: NCT00118898.
Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. [2011.07]
Dolutegravir (DTG) is an unboosted, once-daily integrase inhibitor currently in phase 3 trials. Two studies evaluated the effects of etravirine (ETR) alone and in combination with ritonavir (RTV)-boosted protease inhibitors (PIs) on DTG pharmacokinetics (PK) in healthy subjects... The combination of DTG and ETR alone should be avoided; however, DTG may be coadministered with ETR without a dosage adjustment if LPV/RTV or DRV/RTV is concurrently administered.
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naive HIV-1-infected patients (the ARTEN study). [2011.07]
OBJECTIVES: Dyslipidaemic effects of antiretrovirals (ARVs) may contribute to increased cardiovascular risk (CR) in HIV-1-infected patients. The ARTEN (atazanavir/ritonavir on a background of tenofovir and emtricitabine vs. nevirapine on the same background, in naive HIV-1-infected patients) study compared prospectively ritonavir-boosted atazanavir (ATZ/r) 300 mg/100 mg once daily (qd) with immediate release nevirapine (NVP) 200 mg twice daily or 400 mg qd, each combined with fixed-dose tenofovir 300 mg/emtricitabine 200 mg qd in 569 ARV-naive HIV-1-infected patients. Lipid profiles and CR from baseline to week 48 are reported... CONCLUSIONS: In ARV-naive patients with low CR at the outset, NVP showed a potentially less atherogenic lipid profile compared with ATZ/r. (c) 2011 British HIV Association.
Clinical Trials Related to Norvir (Ritonavir)
Bioequivalence Study of Generic GPO Ritonavir Versus Norvir« [Completed]
To establish bioequivalence of ritonavir generic capsule, with Norvir« as reference drug.
Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART [Completed]
The purpose of this study is to study amprenavir/ritonavir, saquinavir/ritonavir or efavirenz
in HIV-infected patients following failure with Kaletra (ABT-378/ritonavir) as their first
protease inhibitor based HAART.
Bioequivalence Study of Generic GPO Saquinavir and Norvir« Versus Invirase« and Norvir« [Not yet recruiting]
The previous two studies of generic GPO saquinavir failed to prove bioequivalence. In this
study the bio-equivalence will be investigated in healthy Thai volunteers, to see whether
the generic GPO saquinavir shows bioequivalence when boosted with Norvir«. If the generic
formulation is bioequivalent subsequent studies may follow in HIV-1 positive patients.
TMC310911-TiDP21-C201 - A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-naive HIV-1-infected Patients [Recruiting]
The objective of this study is to evaluate the antiviral activity of 4 different doses of
TMC310911 co-administered with ritonavir. TMC310911 is a protease inhibitor with a high
antiviral potency and a high genetic barrier to resistance. Protease inhibitors (PIs) block
the ability of HIV to infect new cells within the body.
DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects [Recruiting]
Darunavir is a nonpeptidic protease inhibitor with a high genetic barrier to resistance that
evolved from a prototype compound synthesized using structure-based design strategies.
Once-daily darunavir at 800mg boosted with 100mg of ritonavir is an effective antiretroviral
agent indicated for HIV-infected treatment-na├»ve patients. In treatment-experienced
patients, darunavir was initially approved for twice-daily administration boosted with
twice-daily ritonavir at 600mg and 100mg, respectively. Recently, once-daily
darunavir/ritonavir was approved for use in treatment-experienced adult patients with
viremia with no darunavir resistance mutations. In treatment-experienced patients with viral
suppression, switching from an antiretroviral taken twice-daily to a once-daily dose is an
attractive option to promote greater patient acceptability and adherence, and potentially
minimize side effects and toxicities. Because of darunavir/ritonavir's high genetic barrier
to resistance and well-established safety profile at a once-daily dose, switching patients
with virologic suppression from twice-daily darunavir/ritonavir to once-daily
darunavir/ritonavir will likely confer attributes more favorable to patients through a
simplified dosing schedule and lower potential for lipid elevation without the loss of
virologic control. DRIVESHAFT is a 48-week Phase 4, randomized, open label, comparative
study. The study will be conducted in 60 HIV-1 infected, antiretroviral experienced,
virologically-suppressed patients on regimens containing darunavir 600mg/ ritonavir 100mg
twice-daily and a minimum of two other antiretrovirals, with a history of 0-1
darunavir-associated resistance mutations. Subjects will be randomized 1: 1 to switch to
darunavir 800mg/ ritonavir 100mg once-daily or continue on their current regimen. Rates of
virologic suppression of once-daily darunavir/ritonavir regimens relative to
darunavir/ritonavir twice-daily regimens will be compared, and safety, change from baseline
fasting lipid parameters, and adherence will be evaluated.
Reports of Suspected Norvir (Ritonavir) Side Effects
Foetal Exposure During Pregnancy (128),
Maternal Exposure During Pregnancy (66),
Abortion Spontaneous (57),
Renal Failure Acute (45),
Premature Baby (39),
Abortion Induced (35),
Drug Interaction (28),
Anaemia (26), more >>
Page last updated: 2015-01-20